Drug-labels.com

Eribulin Mesylate Injection (Marcan Pharmaceuticals): Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
0.5 mg
Active ingredient:
ATC code:

Patient Medication Information: uses, side effects, how to take - Eribulin Mesylate Injection (Marcan Pharmaceuticals)

What the medication is used for:

Eribulin Mesylate Injection is a cancer medicine. It is sold by prescription. It is used to treat:

  • breast cancer that has spread to other parts of the body. It is used when you have had two or more cancer drug treatment plans to treat your breast cancer that has spread.

Eribulin Mesylate Injection is used to treat adult patients with a type of cancer that starts in fat cells called liposarcoma.

Eribuline Mesylate Injection is used if you:

  • can't have an operation to take the cancer out and have liposarcoma that is advanced or has spread to other parts of the body. And,
  • have had other drugs to treat this.

What it does:

Eribulin Mesylate Injection is an anti-cancer agent which works by stopping the growth of cancer cells.

When it should not be used:

Do not use Eribulin Mesylate Injection if you are allergic to eribulin mesylate, or halichondrin B, or any drug related to halichondrin B.

What the medicinal ingredient is:

Eribulin mesylate

What the non-medicinal ingredients are:

Dehydrated Alcohol/Ethanol hydroxide, hydrochloric acid (for pH adjustment), sodium hydroxide (for pH adjustment), water for injection.

What dosage forms it comes in:

Eribulin Mesylate Injection contains 1 mg eribulin mesylate per vial in 2 mL of solution and 1.5 mg eribulin mesylate per vial in 3mL.

BEFORE you use Eribulin Mesylate Injection talk to your doctor or pharmacist about all of your medical conditions, including if you:

  • have low white blood cell counts or low platelet levels
  • have a fever (temperature above 38.1°C) or an infection
  • have heart problems including “prolongation of the QT interval”(changes in heartbeat)
  • experience numbness, tingling or burning in your hands and feet
  • have liver or kidney problems
  • are pregnant or plan to become pregnant. You should not receive Eribulin Mesylate Injection during pregnancy because it may harm your unborn baby. Talk with your health professional about how to prevent pregnancy while receiving Eribulin Mesylate Injection, as you should use effective contraception during and for at least 3 months after receiving Eribulin Mesylate Injection. Tell your health professional right away if you become pregnant or think you are pregnant while receiving Eribulin Mesylate Injection

  • are breast feeding. It is not known if Eribulin Mesylate Injection passes into breast milk. Breast feeding must be avoided.

Eribulin Mesylate Injection may cause drowsiness or tiredness. Do not drive or operate machinery until you know how the medication affects you.

The safety and effectiveness of Eribulin Mesylate Injection in patients under 18 years of age have not been established.

Tell your doctor before taking Eribulin Mesylate Injection if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

ABOUT THIS MEDICATION

WARNINGS AND PRECAUTIONS

INTERACTIONS WITH THIS MEDICATION

Serious Warnings and Precautions

Eribuin Mesylate Injection should be prescribed and managed by a doctor experienced in the use of cancer drugs. Serious side effects with Eribuin Mesylate Injection include:

  • Neutropenia (decrease in the number of white blood cells)
  • Abnormal electrical signal of the heart called “prolongation of the QT interval” (changes in heartbeat)
  • Eribuin Mesylate Injection has not been studied in patients with severe hepatic (liver) impairment or End Stage Renal Disease (ESRD, a disease of the kidney).

IMPORTANT: PLEASE READ

Eribulin Mesylate Injection may interact with the salt levels in the blood (including potassium, calcium, magnesium, following medications: phosphorus and sodium) liver enzymes (called AST, ALT and

  • drugs known to prolong the QT/QC interval and/or cause alkaline phosphatase), protein, bile pigment (bilirubin) and other

    torsade de pointes blood tests such as blood sugar and lactate dehydrogenase (LDH).

  • drugs that decreases electrolyte levels Your doctor will decide when to perform test and will interpret

    the results.

Usual dose: 1.4 mg / m2 body surface area given as an injection into the vein over 2 to 5 minutes on Days 1 and 8 of a 21-day treatment cycle.

Overdose:

Side effects may include:

Very common side effects

  • low white or red blood cell count
  • general weakness
  • fever
  • muscle or joint pain, bone pain
  • headache
  • decreased appetite
  • weight loss
  • shortness of breath
  • cough
  • blisters or sores of the inside of the mouth
  • back pain

Common side effects

  • dizziness, vertigo
  • skin rash, itchiness
  • high or low blood pressure
  • anxiety, depression, trouble sleeping
  • watery eyes
  • dry mouth
  • stomach upset, heartburn
  • chills
  • upper respiratory tract infections (cough, sore throat, runny nose)
  • weight gain
  • changed sense of taste
  • numbness
  • sore throat
  • fast heart rate
  • hoarse voice
  • pain when passing urine
  • sleepiness

Eribulin Mesylate Injection can cause abnormal blood test results. These include changes in bone marrow function tests

(white blood cell count, red blood cell count and platelet count),

Serious side effects and what to do about them

Symptom / effect

Talk to your healthcare professional

Stop taking drug and get immediate medical help

Only if severe

In all cases

VERY COMMON

Tiredness

X

Hair loss

X

Nausea, vomiting, constipation

X

Peripheral neuropathy: Numbness, tingling, or burning in hands and feet

X

Diarrhea

X

Urinary tract infection: fever, chills, burning, pain or difficulty urinating

X

Peripheral edema:

Swelling of hands, feet, or limbs

X

Belly pain or bloating

X

COMMON

Febrile neutropenia: Infection (fever, chills, cough) when your white blood cell

count is low.

X

Thrombocytopenia (low numbers of platelets that are in the blood. These cells help blood

to clot): bruising or taking longer to stop bleeding.

X

Muscle spasms or weakness

X

Prolongation of the QT interval: Changed heart beat

X

Dehydration: feeling thirsty, tired, lightheaded, dry mouth, dark coloured urine and passing urine less often than normal.

X

If you think you, or a person you are caring for, have taken too much Eribulin Mesylate Injection, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

PROPER USE OF THIS MEDICATION

IMPORTANT: PLEASE READ

Serious side effects and what to do about them

Symptom / effect

Talk to your healthcare professional

Stop taking drug and get immediate medical help

Only if severe

In all cases

Serious Skin Reactions (Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis): any combination of red itchy rash with blisters and peeling of the skin and /or of the lips, eyes, mouth, nasal passages or genitals. It often goes with fever, chills, headache, cough, body aches or joint pain. You may have dark urine, yellow skin or

eyes.

X

Atrial fibrillation (irregular heart beat): dizziness, palpitations, racing heartbeat.

X

Pneumonia: productive cough, chest pain, difficulty breathing, fever.

X

Sepsis that can lead to death: fever with a racing heartbeat, rapid shallow breathing, cold, pale, clammy or mottled skin and/or confusion.

X

UNKNOWN FREQUENCY

Interstitial lung disease: Breathing problems including persistent cough and/or shortness

of breath.

X

This is not a complete list of side effects. For any unexpected effects while taking Eribulin Mesylate Injection, contact your doctor or pharmacist.

Store between 15°C to 30°C. Do not freeze.

HOW TO STORE IT

Serious side effects and what to do about them

Symptom / effectTalk to your healthcare professionalStop taking drug and get immediate medical help
Only if severeIn all cases
Hyperglycaemia (high blood sugar): passing urine a lot, thirst and hunger.X

Pulmonary embolism (blood clot on the lung): chest pain, shortness of breath, coughing up

blood.

X

UNCOMMON

Allergic reaction: rash, hives, swelling of the face, lips, tongue

or throat, difficulty swallowing or breathing.

X

Hepatotoxicity (liver damage): belly pain, yellowing of the skin or whites of the eyes, itching.

Nausea, vomiting and loss of appetite.

X
Renal failure (kidneys not working): causing tiredness, not passing urine, swelling in the legs, confusion.X

Deep vein thrombosis (blood clot in the leg): pain, swelling,

redness in the leg.

X

RARE

Pancreatitis (inflammation of the pancreas): severe pain in the upper part of the belly with

nausea and vomiting.

X

Disseminated intravascular coagulation (DIC): a serious disorder of blood clotting resulting in the widespread formation of blood clots and

internal bleeding.

X
Sudden death

IMPORTANT: PLEASE READ

If you want more information about Eribulin Mesylate Injection:

  • Talk to your healthcare professional
  • Find the full product monograph that is prepared for healthcare professionals and includes this Consumer Information by visiting the Health Canada Drug Product Database website (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html); the manufacturer’s website: www.marcanpharma.com, or by calling 1-855-627-2261.

Last Revised: 2026-01-09

Reporting side effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02564467

Revision date stated in the text: January 9, 2026

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Eribulin Mesylate Injection (Marcan Pharmaceuticals)

Rx or OTC
Prescription (Rx)?
DIN 02564467
Schedule(s) PRESCRIPTION
Active ingredient(s) Eribulin mesylate 0.5 MG
Dosage form(s) Solution
Route(s) of administration Intravenous
Drug class (WHO ATC)
  1. L Antineoplastic and immunomodulating agents
    1. L01 Antineoplastic agents
      1. L01X Other antineoplastic agents
        1. L01XX Other antineoplastic agents
          1. L01XX41 Eribulin
Company MARCAN PHARMACEUTICALS INC
Current status Approved
Current status date January 9, 2026

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.